SCHEMBL317148

SCHEMBL317148

N#Cc1cccc(-c2ccccc2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
CTSS P25774 3/20 0.60
MEN1 O00255 2/20 0.60
RAB9A P51151 1/20 0.60
ASIC3 Q9UHC3 1/20 0.50
KDM4E B2RXH2 4/20 0.49
MAPT P10636 2/20 0.49
GAA P10253 1/20 0.49
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 2/20 0.47
GLA P06280 1/20 0.47
POLB P06746 1/20 0.47
LMNA P02545 2/20 0.44
L3MBTL1 Q9Y468 3/20 0.43
ADORA2A P29274 1/20 0.43
ADORA1 P30542 1/20 0.43
MAPK1 P28482 1/20 0.43
ADRB2 P07550 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29988787 0.84 CTSS (0.55) CTSSKDM4ESMN1; SMN2LMNAL3MBTL1
SCHEMBL9220648 0.84 CTSS (0.55) CTSSKDM4ESMN1; SMN2LMNAL3MBTL1
SCHEMBL18422915 0.84 CTSS (0.53) KMT2ACTSSMEN1RAB9AKDM4E
SCHEMBL18462193 0.84 CTSS (0.57) KMT2ACTSSMEN1RAB9AKDM4E
SCHEMBL17116590 0.84 CTSS (0.53) KMT2ACTSSMEN1RAB9AKDM4E
SCHEMBL30518569 0.84 CTSS (0.53) KMT2ACTSSMEN1RAB9AADORA2A
SCHEMBL17117040 0.84 CTSS (0.66) KMT2ACTSSMEN1RAB9AKDM4E
SCHEMBL17116374 0.83 CTSS (0.49) KMT2ACTSSMEN1RAB9AKDM4E
SCHEMBL24345242 0.82 CTSS (0.51) KMT2ACTSSMEN1RAB9AKDM4E
SCHEMBL27901818 0.82 CTSS (0.51) KMT2ACTSSMEN1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2873711-A1 Platinum complexes Centre National de la Recherche Scientifique (C.N.R.S.) (FR) 2015-05-20 EP disclosed
EP-2081903-B1 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2014-05-07 EP disclosed
US-8138348-B2 Using coordination polymerization catalyst EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-03-20 US disclosed
US-8138348-B2 Using coordination polymerization catalyst EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-03-20 US disclosed
US-8138348-B2 Using coordination polymerization catalyst EXXONMOBIL CHEMICAL PATENTS INC. (US) 2012-03-20 US disclosed
US-8093250-B2 2-aminocarbonyl-pyridine derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2012-01-10 US disclosed
CN-101948366-A Method for preparing 4- (diphenylamino) biaryl compound in water phase UNIV DALIAN TECH 2011-01-19 CN disclosed
US-20100286175-A1 2-(Pyridin-2-yl)-pyrimidines and Their Use for Controlling Harmful Fungi GRAMMENOS WASSILIOS 2010-11-11 US disclosed
US-7786043-B2 2-(pyridin-2-yl)-pyrimidines and their use for controlling harmful fungi BASF AKTIENGESELLSCHAFT (DE) 2010-08-31 US disclosed
US-7767665-B2 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-03 US disclosed
US-7399759-B2 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 US disclosed
WO-2008044217-A2 2-AMINOCARBONYL-PYRIDINE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2008-04-17 WO disclosed
US-20080027085-A1 2-(Pyridin-2-Yl)-Pyrimidines and Their Use for Controlling Harmful Fungi BASF AKTIENGESELLSCHAFT (DE) 2008-01-31 US disclosed
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP disclosed
EP-0259139-B1 Pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient SUMITOMO CHEMICAL CO (JP) 1994-01-26 EP disclosed
US-4868178-A FUNGICIDE SUMITOMO CHEMICAL COMPANY, LTD. (JP) 1989-09-19 US disclosed
US-4783466-A Novel pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-11-08 US disclosed
EP-0278610-A2 Novel pyridinyl-s-triazine derivatives, method for production thereof and a fungicide containing them as the active ingredient SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-08-17 EP disclosed
EP-0259139-A2 Pyridinylpyrimidine derivatives, method for production thereof and a plant disease protectant containing them as the active ingredient SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027085-A1 2-(Pyridin-2-Yl)-Pyrimidines and Their Use for Controlling Harmful Fungi CBR1, CBR3, CNPY2 KMT2A 2701/4885CTSS 3882/4885MEN1 2335/4885
US-20100286175-A1 2-(Pyridin-2-yl)-pyrimidines and Their Use for Controlling Harmful Fungi CBR1, CBR3, CNPY2 KMT2A 2701/4885CTSS 3987/4885MEN1 2404/4885
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 KMT2A 3139/4885CTSS 3122/4885MEN1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.